Philips’ new 12-lead, at-home ECG. [Image courtesy of Philips]
The new at-home electrocardiogram monitors could reduce the need for site visits during clinical trials, according to the Dutch medtech giant. At-home ECG is a hot space: iRhythm Technologies CEO Quentin Blackford recently spoke with Medical Design & Outsourcing about iRhythm’s plans to roll out asymptomatic atrial fibrillation (AFib) screening pilots with payors in 2022.
Philips described its device as the industry’s first full-service, at-home, 12-lead electrocardiogram (ECG) for use in decentralized clinical trials. Such full-service, at-home monitoring could reduce patient attrition in clinical trials.
“Our customers are seeking solutions that will help them to address key challenges that can stand in the way of extracting meaningful insights from their clinical trials,” Andy Broadway, GM of Ambulatory Monitoring and Diagnostics at Philips, said in a news release. “Our growing portfolio of remote monitoring solutions help to curb patient attrition by reducing the amount of site visits required during the trial period, helping to improve both the quality of the outcome and the patient experience overall.”
The at-home, 12-lead ECG is now available in select markets across North America, Europe and Asia.
